Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal.
This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ribociclib Treatment Group | HR+/HER2- a/mBC patients with at least 1 month of ribociclib treatment. | ||
| Palbociclib Treatment Group | HR+/HER2- a/mBC patients with at least 1 month of palbociclib treatment. | ||
| Abemaciclib Treatment Group | HR+/HER2- a/mBC patients with at least 1 month of abemaciclib treatment. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients Treated With a CDKI Between November 2018 and May 2023 | Up to approximately 4 years and 6 months | |
| Median Treatment Duration | Up to approximately 4 years and 6 months | |
| Median Time to Next Treatment (TTNT) | TTNT was calculated considering the time between the start of one treatment line and the start of the next treatment line. | Up to approximately 4 years and 6 months |
| Number of Patients With Dose Reductions by Treatment Length per Line of Treatment | Patients were categorized as having 0, 1, or 2 dose reductions over 0-6 months, 7-12 months, and 12 months or more of treatment. | Up to approximately 4 years and 6 months |
Not provided
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |